A Study of AZD8233 in Participants With Dyslipidemia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04641299 |
Recruitment Status :
Completed
First Posted : November 23, 2020
Results First Posted : November 18, 2022
Last Update Posted : November 18, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Dyslipidaemia | Drug: AZD8233 Drug: Placebo | Phase 2 |
This is a randomized parallel, double-blind, placebo-controlled, dose-ranging Phase 2b study in approximately 108 participants with dyslipidemia. The primary objective of the study is to investigate the effect of AZD8233 on LDL-C across different dose levels. The study will be conducted at up to 25 sites in up to 4 countries.
The screening period starts up to 42 days before the randomization visit and ends on Day -1. Eligible participants will attend 7 visits during the treatment period and 7 additional visits during the safety follow up period. Eligible participants are randomized across four different treatment arms in a 1:1:1:1 ratio for a 12-week treatment period. The planned treatment arms are AZD8233 low dose, AZD8233 medium dose, AZD8233 high dose, and Placebo. Participants will be dosed SC on Days 1, 8, 29, and 57.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 119 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Parallel, Double-blind, Placebo-controlled, Dose-ranging, Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD8233 Treatment in Participants With Dyslipidemia |
Actual Study Start Date : | October 28, 2020 |
Actual Primary Completion Date : | July 20, 2021 |
Actual Study Completion Date : | July 20, 2021 |
Arm | Intervention/treatment |
---|---|
Placebo Comparator: Placebo
Placebo solution for subcutaneous injection.
|
Drug: Placebo
Placebo solution |
Experimental: AZD8233 high dose
AZD8233 high dose for subcutaneous injection.
|
Drug: AZD8233
PCSK9-targeted ASO for the reduction of circulating levels of LDL-C. |
Experimental: AZD8233 medium dose
AZD8233 medium dose for subcutaneous injection.
|
Drug: AZD8233
PCSK9-targeted ASO for the reduction of circulating levels of LDL-C. |
Experimental: AZD8233 low dose
AZD8233 low does for subcutaneous injection.
|
Drug: AZD8233
PCSK9-targeted ASO for the reduction of circulating levels of LDL-C. |
- Change in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12. [ Time Frame: Baseline to week 12 ]Change from baseline in low-density lipoprotein cholesterol (LDL-C) at week 12. Results are based on Mixed Model Repeated Measures (MMRM) analysis on the log-transformed change from baseline. Log-transformed change from baseline is calculated as the visit value in log minus the baseline value in log. The results from the model are then back transformed.
- Relative Change From Baseline in PCSK9 Concentration in Plasma at Week 12. [ Time Frame: Baseline to week 12 ]Relative change from baseline in PCSK9 concentration in plasma at week 12.
- Percentage Change From Baseline in Concentration of TC, HDL-C, Non-HDL-C, VLDL-C, ApoA1, ApoB, Lp(a), Triglycerides, Remnants Cholesterol [ Time Frame: Baseline to week 12 ]Percentage change from baseline in concentration of TC, HDL-C, Non-HDL-C, VLDL-C, ApoA1, ApoB, Lp(a), Triglycerides, Remnants cholesterol at week 12
- Plasma Concentration of AZD8233 [ Time Frame: Measurement at week 1, week 4, week 6, week 8, week 10, week 12, week 16, week 20, week 24 after first dose administration. ]Plasma concentration of AZD8233 after first dose administration
- Anti-drug Antibodies (ADAs) During the Treatment Period and Follow-up Period [ Time Frame: Measurement at week 0, week 1, week 4, week 8, week 12, week 16, week 20, week 24 ]ADA titre results for subjects with positive ADA during the treatment period and follow-up period.
- Percentage Change From Baseline in Levels of LDL-C in Plasma [ Time Frame: Baseline to week 12 ]Percentage change from baseline in levels of LDL-C in plasma from baseline to week 12.
- Number of Subjects With an ECG Determined to be Abnormal and Clinically Significant [ Time Frame: Baseline to Week 24 ]Number of subjects with an ECG determined to be abnormal and clinically significant at baseline and end of treatment.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Male or female.
- Participant must be 18 to 75 years of age.
- Body mass index between 19 and 40 kg/m2.
- Participants who have a fasting LDL-C ≥ 70 mg/dL but < 190 mg/dL.
- Have fasting triglycerides < 400 mg/dL.
- Should be receiving moderate- or high-intensity statin therapy.
- Should be on stable medication for ≥ 3 months prior to screening with no planned medication or dose change during study participation. The exception to this restriction is for fenofibrate; if the participant is receiving fenofibrate, the therapy must be stable for at least 6 weeks prior to randomization at a dose that is appropriate for the duration of the study in the judgement of the Investigator. Other fibrate therapy (and derivatives) are prohibited.
Key Exclusion Criteria:
- Estimated glomerular filtration rate < 40 mL/min/1.73m2 CKD-EPI.
- Any uncontrolled or serious disease, or any medical dysfunction or surgical condition that, in the opinion of the Investigator, may either interfere with participation in the clinical study and/or put the participant at significant risk.
- Poorly controlled type 2 diabetes mellitus, defined as HbA1c > 10% at Visit 1.
- Acute ischaemic cardiovascular event in the last 12 months prior to randomization.
- Heart failure with New York Heart Association (NYHA) Class III-IV.
- High-risk of bleeding as judged by the Investigator.
- Malignancy (except non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal
- Carcinoma in-situ, or Stage 1 prostate carcinoma) within the last 10 years.
- LDL or plasma apheresis within 12 months prior to randomization.
- Uncontrolled hypertension defined as average supine SBP > 160 mmHg or DBP > 90 mmHg at Visit 1 or Visit 3.
- Heart rate after 10 minutes supine rest < 50 bpm or > 100 bpm.
-
Any laboratory values with the following deviations at Screening:
- Positive result on screening for hepatitis B, hepatitis C or HIV.
- ALT > 1.5 × ULN.
- AST > 1.5 × ULN.
- TBL > ULN.
- ALP > 1.5 × ULN.
- WBC < LLN.
- Haemoglobin < 12 g/dL in men or < 11 g/dL in women.
- Platelet count ≤ LLN.
- aPTT > ULN and PT > ULN.
- UACR > 11.3 mg/mmol (100 mg/g).
- UPCR > 300 mg/g.
- Any clinically important abnormalities in rhythm, conduction or morphology of the resting ECG and any clinically important abnormalities in the 12-lead ECG as judged by the Investigator.
- Mipomersen, or lomitapide within 12 months prior to randomization.
- Previous administration of AZD8233/AZD6615.
- Previous administration of PCSK9 inhibition treatment.
- Participation in another clinical study with a study intervention administered in the last 3 months prior to randomization or 5 half-lives from last dose to first administration of study intervention, whichever is the longest.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04641299
United States, California | |
Research Site | |
Roseville, California, United States, 95661 | |
United States, Florida | |
Research Site | |
Inverness, Florida, United States, 34452 | |
Research Site | |
Jacksonville, Florida, United States, 32216 | |
Research Site | |
Pembroke Pines, Florida, United States, 33024 | |
United States, Idaho | |
Research Site | |
Meridian, Idaho, United States, 83646 | |
United States, Indiana | |
Research Site | |
Indianapolis, Indiana, United States, 46260 | |
United States, New York | |
Research Site | |
New Windsor, New York, United States, 12553 | |
United States, North Carolina | |
Research Site | |
Greensboro, North Carolina, United States, 27408 | |
United States, North Dakota | |
Research Site | |
Fargo, North Dakota, United States, 58104 | |
United States, Ohio | |
Research Site | |
Cincinnati, Ohio, United States, 45219 | |
Denmark | |
Research Site | |
Aarhus N, Denmark, 8200 | |
Research Site | |
Frederiksberg, Denmark, 2000 | |
Research Site | |
Herlev, Denmark, 2730 | |
Research Site | |
Roskilde, Denmark, 4000 | |
Research Site | |
Viborg, Denmark, 8800 | |
Slovakia | |
Research Site | |
Bratislava, Slovakia, 831 03 | |
Research Site | |
Bratislava, Slovakia, 85101 | |
Research Site | |
Rožňava, Slovakia, 048 01 | |
Research Site | |
Trebišov, Slovakia, 7501 |
Documents provided by AstraZeneca:
Responsible Party: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT04641299 |
Other Study ID Numbers: |
D7990C00003 |
First Posted: | November 23, 2020 Key Record Dates |
Results First Posted: | November 18, 2022 |
Last Update Posted: | November 18, 2022 |
Last Verified: | October 2022 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Dose Range Finding AZD8233 Efficacy PK |
PD Immunogenicity Safety Tolerability |
Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases |